candesartan has been researched along with Hypertension, Renovascular in 14 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hypertension, Renovascular: Hypertension due to RENAL ARTERY OBSTRUCTION or compression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan was administered into the renal artery of nonclipped kidneys to avoid the confounding consequences of decreases in arterial pressure." | 2.40 | Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. ( Cervenka, L; Harrison-Bernard, LM; Imig, JD; Mitchell, KD; Navar, LG; Wang, CT, 1999) |
| "Atherosclerotic renal artery stenosis is a problem with no consensus on diagnosis or therapy." | 1.33 | Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. ( Cohen, DJ; Cooper, CJ; D'Agostino, R; Dworkin, L; Henrich, W; Jaff, M; Jamerson, K; Kuntz, R; Matsumoto, A; Murphy, TP; Reid, D; Rosenfield, K; Rundback, J; Steffes, M, 2006) |
| "Also, low-dose perindopril prevented cardiac hypertrophy and fibrosis." | 1.32 | Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. ( Horikoshi, K; Izumi, T; Mochizuki, S; Nagai, M; Seki, S; Taniguchi, I; Taniguchi, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshide, S | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Palm, F | 2 |
| Onozato, M | 1 |
| Welch, WJ | 3 |
| Wilcox, CS | 3 |
| Mendonca, M | 2 |
| Aslam, S | 1 |
| Hirayama, T | 1 |
| Takahashi, F | 1 |
| Kikuchi, K | 1 |
| Duke, LM | 1 |
| Widdop, RE | 1 |
| Kett, MM | 1 |
| Evans, RG | 1 |
| Nagai, M | 1 |
| Horikoshi, K | 1 |
| Izumi, T | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| Bivol, LM | 1 |
| Vågnes, OB | 1 |
| Iversen, BM | 1 |
| Theilig, F | 1 |
| Debiec, H | 1 |
| Nafz, B | 1 |
| Ronco, P | 1 |
| Nüsing, R | 1 |
| Seyberth, HW | 1 |
| Pavenstädt, H | 1 |
| Bouby, N | 1 |
| Bachmann, S | 1 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Matsumoto, A | 1 |
| Steffes, M | 1 |
| Cohen, DJ | 1 |
| Jaff, M | 1 |
| Kuntz, R | 1 |
| Jamerson, K | 1 |
| Reid, D | 1 |
| Rosenfield, K | 1 |
| Rundback, J | 1 |
| D'Agostino, R | 1 |
| Henrich, W | 1 |
| Dworkin, L | 1 |
| Connors, SG | 1 |
| Jin, D | 1 |
| Takai, S | 1 |
| Shiota, N | 1 |
| Miyazaki, M | 1 |
| Cervenka, L | 2 |
| Wang, CT | 2 |
| Mitchell, KD | 2 |
| Navar, LG | 2 |
| Harrison-Bernard, LM | 1 |
| Imig, JD | 1 |
| Nyström, HC | 1 |
| Jia, J | 1 |
| Johansson, M | 1 |
| Lambert, G | 1 |
| Bergström, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
2 reviews available for candesartan and Hypertension, Renovascular
| Article | Year |
|---|---|
[Secondary nephrotic syndrome due to cardiovascular disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diagnosis, Differential | 2004 |
Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; B | 1999 |
12 other studies available for candesartan and Hypertension, Renovascular
| Article | Year |
|---|---|
Ischemic nephropathy in an elderly patient.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Female; Humans; | 2008 |
Blood pressure, blood flow, and oxygenation in the clipped kidney of chronic 2-kidney, 1-clip rats: effects of tempol and Angiotensin blockade.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pr | 2010 |
Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cyclic N-Oxides; Hemo | 2003 |
AT(2) receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Anima | 2005 |
Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2004 |
The renal vascular response to ANG II injection is reduced in the nonclipped kidney of two-kidney, one-clip hypertension.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; B | 2005 |
Renal cortical regulation of COX-1 and functionally related products in early renovascular hypertension (rat).
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2006 |
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Biph | 2006 |
Angiotensin II type 2 receptors and nitric oxide sustain oxygenation in the clipped kidney of early Goldblatt hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; B | 1998 |
Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; B | 1999 |
Neurohormonal influences on maintenance and reversal of two-kidney one-clip renal hypertension.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Catecholamines; Heart R | 2002 |